X4 Pharmaceuticals, Inc.
XFORNASDAQHealthcare● Active
$3.71
$-0.12(-3.13%)
Market Cap$349926072
P/E Ratio—
52W High$4.83
52W Low$1.35
X4 Pharmaceuticals, Inc. (XFOR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
XFOR · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.16
Est. -$0.20 · +20.0%
Revenue
$0.00B
Est. $0.00B · -22.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue🔥 5-Quarter EPS Beat Streak
XFOR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.12
Rev. $4.47B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.12
Rev. Est.$4.47B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.19 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 6, 2026 | -$0.20 | -$0.16 | +20.0% | $0.00B | $0.00B | -22.8% |
| ▲ Q1 FY2026 | Mar 17, 2026 | -$0.36 | -$0.22 | +38.9% | $0.00B | $0.00B | +48.2% |
| ▲ Q4 FY2025 | Nov 5, 2025 | -$0.79 | -$0.69 | +12.7% | $0.00B | $0.00B | +1.9% |
| ▲ Q3 FY2025 | Aug 8, 2025 | -$4.53 | -$3.47 | +23.4% | $0.00B | $0.00B | -11.4% |
| ▲ Q2 FY2025 | May 1, 2025 | -$4.13 | $0.04 | +101.0% | $0.03B | $0.00B | +1416.2% |
| ▼ Q1 FY2025 | Mar 25, 2025 | -$5.11 | -$6.01 | -17.6% | $0.00B | $0.00B | -35.8% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.17 | -$0.18 | -5.9% | $0.00B | $0.00B | -45.0% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.19
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
-$0.16
EPS Est.
-$0.20
EPS Surpr.
+20.0%
Revenue
$0.00B
Q1 FY2026
Mar 17, 2026Beat
EPS Actual
-$0.22
EPS Est.
-$0.36
EPS Surpr.
+38.9%
Revenue
$0.00B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
-$0.69
EPS Est.
-$0.79
EPS Surpr.
+12.7%
Revenue
$0.00B
Q3 FY2025
Aug 8, 2025Beat
EPS Actual
-$3.47
EPS Est.
-$4.53
EPS Surpr.
+23.4%
Revenue
$0.00B
Q2 FY2025
May 1, 2025Beat
EPS Actual
$0.04
EPS Est.
-$4.13
EPS Surpr.
+101.0%
Revenue
$0.03B
Q1 FY2025
Mar 25, 2025Miss
EPS Actual
-$6.01
EPS Est.
-$5.11
EPS Surpr.
-17.6%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.18
EPS Est.
-$0.17
EPS Surpr.
-5.9%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.28 | $-0.22 | $-0.13 | 1 |
| Q3 FY2027 | $-0.25 | $-0.20 | $-0.12 | 1 |
| Q2 FY2027 | $-0.25 | $-0.20 | $-0.12 | 1 |
| Q1 FY2027 | $-0.26 | $-0.21 | $-0.12 | 1 |
| Q4 FY2026 | $-0.26 | $-0.20 | $-0.12 | 1 |
| Q3 FY2026 | $-0.22 | $-0.19 | $-0.15 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +20.0% | $4.20 | $4.38 | +4.29% |
| ▲ Q1 FY2026 | Mar 17, 2026 | +38.9% | $3.56 | $4.23 | +18.82% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +12.7% | $3.97 | $3.55 | -10.58% |
| ▲ Q3 FY2025 | Aug 8, 2025 | +23.4% | $1.46 | $1.49 | +2.05% |
| ▲ Q2 FY2025 | May 1, 2025 | +101.0% | $4.31 | $3.75 | -12.99% |
| ▼ Q1 FY2025 | Mar 25, 2025 | -17.6% | $8.85 | $7.78 | -12.09% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -5.9% | $17.76 | $8.32 | -53.15% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -40.0% | $18.93 | $19.54 | +3.22% |
Q2 FY2026+4.29%
Report Date
May 6, 2026
EPS Beat/Miss
+20.0%
Price Before
$4.20
Price After
$4.38
Q1 FY2026+18.82%
Report Date
Mar 17, 2026
EPS Beat/Miss
+38.9%
Price Before
$3.56
Price After
$4.23
Q4 FY2025-10.58%
Report Date
Nov 5, 2025
EPS Beat/Miss
+12.7%
Price Before
$3.97
Price After
$3.55
Q3 FY2025+2.05%
Report Date
Aug 8, 2025
EPS Beat/Miss
+23.4%
Price Before
$1.46
Price After
$1.49
Q2 FY2025-12.99%
Report Date
May 1, 2025
EPS Beat/Miss
+101.0%
Price Before
$4.31
Price After
$3.75
Q1 FY2025-12.09%
Report Date
Mar 25, 2025
EPS Beat/Miss
-17.6%
Price Before
$8.85
Price After
$7.78
Q4 FY2024-53.15%
Report Date
Nov 13, 2024
EPS Beat/Miss
-5.9%
Price Before
$17.76
Price After
$8.32
Q3 FY2024+3.22%
Report Date
Aug 8, 2024
EPS Beat/Miss
-40.0%
Price Before
$18.93
Price After
$19.54
Avg Beat Reaction+0.32%
Avg Miss Reaction-20.67%
Beat Rate5 / 8 quarters
Largest Move-53.15% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: XFOR ends December
X4 Pharmaceuticals, Inc. (XFOR) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.16 — beating the analyst consensus of $-0.20 by +20.0%. XFOR has beaten EPS estimates for 5 consecutive quarters. The next XFOR earnings date is expected around September 1, 2026.
Each quarter, investors track XFOR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. XFOR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
XFOR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
XFOR earnings · 5 questionsX4 Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. XFOR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; XFOR historically reports after market close (AMC).
XFOR earnings datewhen is XFOR earningsXFOR next earnings datewhen does XFOR report earningsXFOR earnings calendar
▸ Source: FMP · X4 Pharmaceuticals, Inc. SEC filings · US GAAP · X4 Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026